Cargando…

Experimental identification of cancer driver alterations in the era of pan‐cancer genomics

Rapidly accumulating data from large‐scale cancer genomics studies have been generating important information about genes and their somatic alterations underlying cell transformation, cancer onset and tumor progression. However, these events are usually defined by using computational techniques, whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Korenjak, Michael, Zavadil, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890429/
https://www.ncbi.nlm.nih.gov/pubmed/31594033
http://dx.doi.org/10.1111/cas.14210
_version_ 1783475608071700480
author Korenjak, Michael
Zavadil, Jiri
author_facet Korenjak, Michael
Zavadil, Jiri
author_sort Korenjak, Michael
collection PubMed
description Rapidly accumulating data from large‐scale cancer genomics studies have been generating important information about genes and their somatic alterations underlying cell transformation, cancer onset and tumor progression. However, these events are usually defined by using computational techniques, whereas the understanding of their actual functional roles and impact typically warrants validation by experimental means. Critical information has been obtained from targeted genetic perturbation (gene knockout) studies conducted in animals, yet these investigations are cost‐prohibitive and time‐consuming. In addition, the 3R principles (replacement, reduction, refinement) have been set in place to reduce animal use burden and are increasingly observed in many areas of biomedical research. Consequently, the focus has shifted to new designs of innovative cell‐based experimental models of cell immortalization and transformation in which the critical cancer driver events can be introduced by mutagenic insult and studied functionally, at the level of critical phenotypic readouts. From these efforts, primary cell‐based selective barrier‐bypass models of cell immortalization have emerged as an attractive system that allows studies of the functional relevance of acquired mutations as well as their role as candidate cancer driver events. In this review, we provide an overview of various experimental systems linking carcinogen exposure‐driven cell transformation with the study of cancer driver events. We further describe the advantages and disadvantages of the currently available cell‐based models while outlining future directions for in vitro modeling and functional testing of cancer driver events.
format Online
Article
Text
id pubmed-6890429
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68904292019-12-12 Experimental identification of cancer driver alterations in the era of pan‐cancer genomics Korenjak, Michael Zavadil, Jiri Cancer Sci Review Articles Rapidly accumulating data from large‐scale cancer genomics studies have been generating important information about genes and their somatic alterations underlying cell transformation, cancer onset and tumor progression. However, these events are usually defined by using computational techniques, whereas the understanding of their actual functional roles and impact typically warrants validation by experimental means. Critical information has been obtained from targeted genetic perturbation (gene knockout) studies conducted in animals, yet these investigations are cost‐prohibitive and time‐consuming. In addition, the 3R principles (replacement, reduction, refinement) have been set in place to reduce animal use burden and are increasingly observed in many areas of biomedical research. Consequently, the focus has shifted to new designs of innovative cell‐based experimental models of cell immortalization and transformation in which the critical cancer driver events can be introduced by mutagenic insult and studied functionally, at the level of critical phenotypic readouts. From these efforts, primary cell‐based selective barrier‐bypass models of cell immortalization have emerged as an attractive system that allows studies of the functional relevance of acquired mutations as well as their role as candidate cancer driver events. In this review, we provide an overview of various experimental systems linking carcinogen exposure‐driven cell transformation with the study of cancer driver events. We further describe the advantages and disadvantages of the currently available cell‐based models while outlining future directions for in vitro modeling and functional testing of cancer driver events. John Wiley and Sons Inc. 2019-10-31 2019-12 /pmc/articles/PMC6890429/ /pubmed/31594033 http://dx.doi.org/10.1111/cas.14210 Text en © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Korenjak, Michael
Zavadil, Jiri
Experimental identification of cancer driver alterations in the era of pan‐cancer genomics
title Experimental identification of cancer driver alterations in the era of pan‐cancer genomics
title_full Experimental identification of cancer driver alterations in the era of pan‐cancer genomics
title_fullStr Experimental identification of cancer driver alterations in the era of pan‐cancer genomics
title_full_unstemmed Experimental identification of cancer driver alterations in the era of pan‐cancer genomics
title_short Experimental identification of cancer driver alterations in the era of pan‐cancer genomics
title_sort experimental identification of cancer driver alterations in the era of pan‐cancer genomics
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890429/
https://www.ncbi.nlm.nih.gov/pubmed/31594033
http://dx.doi.org/10.1111/cas.14210
work_keys_str_mv AT korenjakmichael experimentalidentificationofcancerdriveralterationsintheeraofpancancergenomics
AT zavadiljiri experimentalidentificationofcancerdriveralterationsintheeraofpancancergenomics